


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Currently Amended) A compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:



wherein

R₁ and R₃ independently represent H; F; Cl; Br; -NO₂; -CN; C₁-C₆ alkyl optionally substituted by F or Cl; or C₁-C₆ alkoxy optionally substituted by F;

R₂ represents H, or optionally substituted C₁-C₆ alkyl, C₃-C₇ cycloalkyl or optionally substituted phenyl;

Y represents -O-, -S-, N-oxide, or -N(R₅)- wherein R₅ represents H or C₁-C₆ alkyl;

X represents a bond or a divalent C₁-C₆ alkylene radical;

R₄ represents -C(=O)NR₆R₇, ~~NR₇C(=O)R₆~~, ~~NR₇C(=O)OR₆~~, ~~NHC(=O)NHR₆~~ or ~~NHC(=S)NHR₆~~ wherein

R₆ represents ~~H~~, or a radical of formula -(Alk)_b-Q wherein b is ~~0~~ or 1 and

Alk is an optionally substituted divalent straight chain or branched C₁-C₁₂ alkylene, C₂-C₁₂ alkenylene or C₂-C₁₂ alkynylene radical which may be interrupted by one or more

non-adjacent -O-, -S- or -N(R₈)- radicals wherein R₈ represents H or C₁-C₄ alkyl, C₃-C₄ alkenyl, C₃-C₄ alkynyl, or C₃-C₆ cycloalkyl, and

Q represents H; -CF₃; -OH; -SH; -NR₈R₈ wherein each R₈ may be the same or different; an ester group; or an optionally substituted phenyl, C₃-C₇ cycloalkyl, C₅-C₇ cycloalkenyl or heterocyclic ring having from 5 to 8 ring atoms; and

R₇ represents H or C₁-C₆ alkyl; or when taken together with the atom or atoms to which they are attached R₆ and R₇ form an optionally substituted heterocyclic ring having from 5 to 8 ring atoms;

~~provided that when R₁, R₂, and R₃ are all H, Y is -NH-, and X represents a bond, then R₄ may not be C(=O)NR₆R₇, wherein R₆ and R₇ are H, or NHC(=O)NHR₆, wherein R₆ is -(Alk)_b-Q wherein b is 1, Alk is C₄-alkylene and Q is H.~~

Claim 2. (Original) A compound as claimed in claim 1 wherein R₁ is H, F, Cl, methyl or methoxy.

Claim 3. (Previously Presented) A compound as claimed in claim 1 wherein R₂ is H, methyl, methoxy, cyclopropyl, phenyl, or fluoro-, chloro-, methyl, or methoxy-substituted phenyl.

Claim 4. (Previously Presented) A compound as claimed in claim 1 wherein R₃ is H, F, Cl, methyl, or methoxy.

Claim 5. (Previously Presented) A compound as claimed in claim 1 wherein Y is -O-, -S-, or -N(R₅)- wherein R₅ represents H or methyl.

Claim 6. (Previously Presented) A compound as claimed in claim 1 wherein X is a bond, or a -CH₂- or -CH₂CH₂- radical.

Claim 7. (Currently Amended) A compound as claimed in claim 1 wherein R_4 represents $-C(=O)NHR_6$, $-NR_7C(=O)R_6$, $-NR_7C(=O)OR_6$, $-NHC(=O)NHR_6$ or $-NHC(=S)NHR_6$ and in these wherein R_6 is H or a radical of formula $-Alk_b-Q$ wherein b is 0 or 1 and

Alk is a $-(CH_2)_n-$, $-CH((CH_2)_mCH_3)(CH_2)_n-$, $-CH((CH_2)_mCH_3)((CH_2)_pCH_3)(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_m-$, or $-(CH_2)_n-O-(CH_2)_n-O-(CH_2)_m-$, radical where n is 1, 2, 3 or 4 and m and p are independently 0, 1, 2, 3 or 4, and Q represents H, $-OH$, $-COOCH_3$ phenyl, cyclopropyl, cyclopentyl, cyclohexyl, pyridyl, furyl, thienyl, or oxazolyl, and

R_7 is H, or when taken together with the nitrogen atom to which they are attached R_6 and R_7 form a pyrrolidine 2-one or pyrrolidine 2,5-dione ring.

Claim 8. (Currently Amended) A compound as claimed in claim 1 wherein R_1 is H, F, or Cl; R_2 is H; R_3 is H, F, or Cl; Y is $-NH-$; X is a bond; and R_4 represents $-C(=O)NHR_6$, $-NR_7C(=O)R_6$, $-NR_7C(=O)OR_6$ or $-NHC(=O)NHR_6$ wherein:

R_6 is H or a radical of formula $-Alk_b-Q$ wherein

b is 0 or 1 and

Alk is a $-(CH_2)_n-$, $-CH((CH_2)_mCH_3)(CH_2)_n-$, $-CH((CH_2)_mCH_3)((CH_2)_pCH_3)(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_m-$, or $-(CH_2)_n-O-(CH_2)_n-O-(CH_2)_m-$, radical where n is 1, 2, 3 or 4 and m and p are independently 0, 1, 2, 3 or 4, and Q represents H, $-OH$, $-COOCH_3$ phenyl, cyclopropyl, cyclopentyl, cyclohexyl, pyridyl, furyl, thienyl, or oxazolyl, and

R_7 is H, or when taken together with the nitrogen atom to which they are attached R_6 and R_7 form a pyrrolidine 2-one or pyrrolidine 2,5-dione ring.


Claim 9. (Currently Amended) A compound as claimed in claim 1 wherein R_1 is F, R_2 is H or cyclopropyl, R_3 is H, X is a bond, and R_4 is $-C(=O)NHR_6$, $-NHC(=O)R_6$, or $-NHC(=O)NHR_6$.

Claim 10. (Original) N-(3-Dimethylamino propyl)-4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzamide, or pharmaceutically or veterinarily acceptable salt thereof.

Claim 11. (Canceled)

Claim 12. (Canceled)

Claim 13. (Previously Presented) A method of immunomodulation in humans and non-human primates, comprising administration to a subject in need of such treatment an immunomodulatory effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:



wherein

R₁ and R₃ independently represent H; F; Cl; Br; -NO₂; -CN; C₁-C₆ alkyl optionally substituted by F or Cl; or C₁-C₆ alkoxy optionally substituted by F;

R₂ represents H, or optionally substituted C₁-C₆ alkyl, C₃-C₇ cycloalkyl or optionally substituted phenyl;

Y represents -O-, -S-, N-oxide, or -N(R₅)- wherein R₅ represents H or C₁-C₆ alkyl;

X represents a bond or a divalent C₁-C₆ alkylene radical;

R₄ represents -C(=O)NR₆R₇, -NR₇C(=O)R₆, -NR₇C(=O)OR₆, -NHC(=O)NHR₆ or -NHC(=S)NHR₆ wherein

R₆ represents H, or a radical of formula -(Alk)_b-Q wherein b is 0 or 1 and

Alk is an optionally substituted divalent straight chain or branched C₁-C₁₂ alkylene, C₂-C₁₂ alkenylene or C₂-C₁₂ alkynylene radical which may be interrupted by one or more non-adjacent -O-, -S- or -N(R₈)- radicals wherein R₈ represents H or C₁-C₄ alkyl, C₃-C₄ alkenyl, C₃-C₄ alkynyl, or C₃-C₆ cycloalkyl, and

Q represents H; -CF₃; -OH; -SH; -NR₈R₈ wherein each R₈ may be the same or different; an ester group; or an optionally substituted phenyl, C₃-C₇ cycloalkyl, C₅-C₇ cycloalkenyl or heterocyclic ring having from 5 to 8 ring atoms; and

R₇ represents H or C₁-C₆ alkyl; or when taken together with the atom or atoms to which they are attached R₆ and R₇ form an optionally substituted heterocyclic ring having from 5 to 8 ring atoms.

Claim 14. (Previously Presented) A pharmaceutical or veterinary composition comprising a compound as claimed in claim 1 together with a pharmaceutically or veterinarily acceptable excipient or carrier.

Claim 15. (Previously Presented) A compound as claimed in claim 2 wherein R₂ is H, methyl, methoxy, cyclopropyl, phenyl, or fluoro-, chloro-, methyl, or methoxy-substituted phenyl.

Claim 16. (Previously Presented) A compound as claimed in claim 2 wherein R₃ is H, F, Cl, methyl, or methoxy.

Claim 17. (Previously Presented) A compound as claimed in claim 3 wherein R₃ is H, F, Cl, methyl, or methoxy.

Claim 18. (Previously Presented) A compound as claimed in claim 15 wherein R₃ is H, F, Cl, methyl, or methoxy.

Claim 19. (Previously Presented) A compound as claimed in claim 2 wherein Y is -O-, -S-, or -N(R₅)- wherein R₅ represents H or methyl.

Claim 20. (Previously Presented) A compound as claimed in claim 2 wherein X is a bond, or a $-\text{CH}_2-$ or $-\text{CH}_2\text{CH}_2-$ radical.

Claim 21. (Currently Amended) A compound as claimed in claim 2 wherein R_4 represents $-\text{C}(=\text{O})\text{NHR}_6$, $-\text{NR}_7\text{C}(=\text{O})\text{R}_6$, $-\text{NR}_7\text{C}(=\text{O})\text{OR}_6$, $-\text{NHC}(=\text{O})\text{NHR}_6$ or $-\text{NHC}(=\text{S})\text{NHR}_6$ and in these wherein R_6 is H or a radical of formula $-\text{Alk}_b-\text{Q}$ wherein b is 0 or 1 and

Alk is a $-(\text{CH}_2)_n-$, $-\text{CH}((\text{CH}_2)_m\text{CH}_3)(\text{CH}_2)_n-$, $-\text{CH}((\text{CH}_2)_m\text{CH}_3)((\text{CH}_2)_p\text{CH}_3)(\text{CH}_2)_n-$, $-(\text{CH}_2)_n-\text{O}-(\text{CH}_2)_m-$, or $-(\text{CH}_2)_n-\text{O}-(\text{CH}_2)_n-\text{O}-(\text{CH}_2)_m-$, radical where n is 1, 2, 3 or 4 and m and p are independently 0, 1, 2, 3 or 4, and Q represents H, $-\text{OH}$, $-\text{COOCH}_3$ phenyl, cyclopropyl, cyclopentyl, cyclohexyl, pyridyl, furyl, thienyl, or oxazolyl, and

~~R_7 is H, or when taken together with the nitrogen atom to which they are attached R_6 and R_7 form a pyrrolidine 2-one or pyrrolidine 2,5-dione ring.~~

Claim 22. (Previously Presented) A method of immunomodulation in humans and non-human primates, comprising administration to a subject in need of such treatment an immunomodulatory effective dose of a compound as claimed in claim 2.

Claim 23. (Previously Presented) A method of immunomodulation in humans and non-human primates, comprising administration to a subject in need of such treatment an immunomodulatory effective dose of a compound as claimed in claim 3.

Claim 24. (Previously Presented) A pharmaceutical or veterinary composition comprising a compound as claimed in claim 2 together with a pharmaceutically or veterinarily acceptable excipient or carrier.

Claim 25. (Previously Presented) A pharmaceutical or veterinary composition comprising a compound as claimed in claim 3 together with a pharmaceutically or veterinarily acceptable excipient or carrier.